CDEK
← All drugs Report issue

encenicline

Small moleculeexperimental

Encenicline is a selective partial agonist of the α7 nicotinic receptor. It was in phase III clinical trials for the treatment of cognitive impairment in schizophrenia, but failed to meet the study endpoints in 2016. — Wikipedia

Clinical trial activity

19 trials · 13 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
14
Phase 3
7
Phase 4
0

Earliest trial started Apr 1, 2008 (NCT01556763)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2009

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C(N[C@H]1CN2CCC1CC2)c1cc2cccc(Cl)c2s1
Mol. weight
320.85 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 7-chloro-n-quinuclidin-3-yl-benzo(b)thiophene-2-carboxamide
  • amg 747
  • encenicline
  • encenicline
  • encenicline
  • encenicline
  • encenicline hydrochloride
  • encenicline hydrochloride
  • evp-6124
  • evp-6124
  • evp-6124
  • evp-6124
  • mt-4666
  • mt-4666
  • mt-4666
  • n-(7-chloro-n-quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02246075Phase 2Jul 1, 2015FORUM Pharmaceuticals Inc, IQVIA
NCT02327182Phase 3Dec 1, 2014Kagawa University, Mitsubishi Tanabe
NCT02004392Phase 3Jun 1, 2014FORUM Pharmaceuticals Inc
NCT01969123Phase 3Oct 1, 2013FORUM Pharmaceuticals Inc
NCT01969136Phase 3Oct 1, 2013FORUM Pharmaceuticals Inc
NCT01714713Phase 3Jun 1, 2013FORUM Pharmaceuticals Inc, INC Research
NCT01984723Phase 1Jun 1, 2013FORUM Pharmaceuticals Inc, Pharmaceutical Research Associates, Inc. (PRA)
NCT01984736Phase 1Jun 1, 2013FORUM Pharmaceuticals Inc, Pharmaceutical Research Associates, Inc. (PRA)
NCT01764243Phase 2Nov 1, 2012Kagawa University, Mitsubishi Tanabe, Sapporo Medical University, Tokyo Dementia Care Research and Training Center
NCT01714661Phase 3Oct 1, 2012FORUM Pharmaceuticals Inc, INC Research, VeraSci
NCT01716975Phase 3Oct 1, 2012FORUM Pharmaceuticals Inc, INC Research, VeraSci
NCT01568229Phase 2May 1, 2012Amgen
NCT01568216Phase 2May 1, 2012Amgen
NCT01487135Phase 1Dec 1, 2011FORUM Pharmaceuticals Inc, IQVIA
NCT01480232Phase 2Dec 1, 2011FORUM Pharmaceuticals Inc, Harvard University, National Institute on Drug Abuse (NIDA)
NCT01073228Phase 2Apr 1, 2010FORUM Pharmaceuticals Inc, INC Research
NCT00968851Phase 2Dec 1, 2009FORUM Pharmaceuticals Inc, INC Research
NCT00766363Phase 1Oct 1, 2008FORUM Pharmaceuticals Inc, INC Research, Pacific Research Network, Inc.
NCT01556763Phase 1Apr 1, 2008FORUM Pharmaceuticals Inc
Showing 19 of 19 trials
Page 1 / 1

Organizations

Research & Development (13)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
FORUM Pharmaceuticals IncFor profit151432008
INC ResearchFor profit6032008
AmgenFor profit2212012
IQVIAFor profit2022011
Kagawa UniversityAcademic/Hospital2022012
Mitsubishi TanabeFor profit2222012
Pharmaceutical Research Associates, Inc. (PRA)For profit2012013
VeraSciFor profit2012012
Harvard UniversityAcademic/Hospital1112011
National Institute on Drug Abuse (NIDA)Government1012011
Pacific Research Network, Inc.For profit1012008
Sapporo Medical UniversityAcademic/Hospital1012012
Tokyo Dementia Care Research and Training CenterAcademic/Hospital1012012
13 organizations
Page 1 / 1